If you purchase through a BGR link, we may earn an associate commission, helping our specialty product labs.
Dr. Anthony Fauci explained a few days ago that the main goal of the first generation of coronavirus vaccines was not to block infection yet to save severe disease. If they block the infection, that would be an even greater result. But doctors must save you serious ailments and save lives with those medications.
It’s unclear whether the vaccines will work, although all of the pioneers have shown great promise in lab tests and earlier stages of clinical trials. Not all of the clinical network is betting on the good luck of vaccines, and many studies are looking for short-term results. possible remedies for COVID-19, as well as medications that can lessen the threat of infection. Scientists at the Indian Institute of Medical Sciences (AIIMS) in Bhubaneswar have a drug that can decrease the chances of infection, and it’s a substance I’ve heard of before.
Researchers conducted in vitro tests with ivermectin and found that the drug was effective in blocking SARS-CoV-2. They published its effects in early April, emphasizing that studies in real patients will be necessary to determine if the drug is truly effective. Ivermectin is already an internationally approved drug and can treat various diseases caused by all types of pathogens, including lice, scabies and various worms. The drug has been used against other infectious diseases, such as HIV, dengue and Zika.
Researchers at AIIMS-Bhubaneshwar conducted a study between September 20 and October 19 and concluded that two doses of ivermectin taken prophylactically resulted in 73% relief in COVID-19 infections, raising some questions.
The doctors decided on 372 healthcare personnel for the study, some of whom tested positive for COVID-19. They divided the patients into other organizations, and each of them took another prophylaxis, adding a single dose of ivermectin (77 negative and 38 positive); vitamin C (38 negative and 29 positive); double dose of ivermectin 3 days apart (94 participants, but 26 did not adhere to the two-dose regimen); and hydroxychloroquine (12 negative and 6 positive). It is unclear why hydroxychloroquine, a drug that studies have so far shown is useless in blocking or treating COVID-19, was included.
The scientists concluded that ivermectin could reduce the risk of transmission, while vitamin C and hydroxychloroquine had no effect. “Previously, at least 20 to 25 [health workers] were inflamed daily by the virus,” said AIIMS director Gitanjali Batmanabane. “While among those taking ivermectin, the number of infections has dropped to one or two per day. But researchers say a single dose of ivermectin did not reduce infection rates.
The effects look promising at first glance, but some questions still remain. This was not a randomized, double-blind, placebo-controlled study, which is popular for clinical trials, but rather an observational study. A randomized trial comparing ivermectin with popular care may simply be more important whether the drug has real prophylactic effects and whether it is effective in treating COVID-19. After all, some of the patients who won the drug as a component of this trial were already infected with the coronavirus. The study has not been reviewed and is not available in preprint form at this link.
Crumpe’s audience craves our state-of-the-art data on the latest generation and entertainment, as well as our detailed and authoritative reviews.
We advise our unwavering readers on some of the most productive products, latest trends, and most interesting stories with non-stop coverage, available on all major news platforms.
Founded in 2006
More than 2 billion visitors
More than 100,000 articles published
Millions of readers helped